Similarly, specific lipid subspecies predicted risk of progression in individuals with MCI compared to preclinical AD individuals (with increased CSF p-tau/Aβ1-42 ratio), even when adjusted for APOE ε4 status (HR = 1.97–1.99) [192]. The gene discussed is MAPT; the disease is Alzheimer disease.